Eda Isil Altiok
University of California, Berkeley
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eda Isil Altiok.
PLOS ONE | 2011
Tan Truong; Eda Isil Altiok; Don Yuen; Tatiana Ecoiffier; Lu Chen
Lymphatic research has progressed rapidly in recent years. Though lymphatic dysfunction has been found in a wide array of disorders from transplant rejection to cancer metastasis, to date, there is still little effective treatment for lymphatic diseases. The cornea offers an optimal site for lymphatic research due to its accessible location, transparent nature, and lymphatic-free but inducible features. However, it still remains unknown whether lymphatic valves exist in newly formed lymphatic vessels in the cornea, and how this relates to an inflammatory response. In this study, we provide the first evidence showing that lymphatic valves were formed in mouse cornea during suture-induced inflammation with the up-regulation of integrin alpha 9. The number of corneal valves increased with the progression of inflammatory lymphangiogenesis. Moreover, we have detected lymphatic valves at various developmental stages, from incomplete to more developed ones. In addition to defining the average diameter of lymphatic vessels equipped with lymphatic valves, we also report that lymphatic valves were more often located near the branching points. Taken together, these novel findings not only provide new insights into corneal lymphatic formation and maturation, but also identify a new model for future investigation on lymphatic valve formation and possibly therapeutic intervention.
PLOS ONE | 2016
Eda Isil Altiok; Shane Browne; Emily Khuc; Elizabeth P. Moran; Fangfang Qiu; Kelu Zhou; Jorge L. Santiago-Ortiz; Jian Xing Ma; Matilda F. Chan; Kevin E. Healy
Current anti-VEGF drugs for patients with diabetic retinopathy suffer from short residence time in the vitreous of the eye. In order to maintain biologically effective doses of drug for inhibiting retinal neovascularization, patients are required to receive regular monthly injections of drug, which often results in low patient compliance and progression of the disease. To improve the intravitreal residence time of anti-VEGF drugs, we have synthesized multivalent bioconjugates of an anti-VEGF protein, soluble fms-like tyrosine kinase-1 (sFlt) that is covalently grafted to chains of hyaluronic acid (HyA), conjugates that are termed mvsFlt. Using a mouse corneal angiogenesis assay, we demonstrate that covalent conjugation to HyA chains does not decrease the bioactivity of sFlt and that mvsFlt is equivalent to sFlt at inhibiting corneal angiogenesis. In a rat vitreous model, we observed that mvsFlt had significantly increased intravitreal residence time compared to the unconjugated sFlt after 2 days. The calculated intravitreal half-lives for sFlt and mvsFlt were 3.3 and 35 hours, respectively. Furthermore, we show that mvsFlt is more effective than the unconjugated form at inhibiting retinal neovascularization in an oxygen-induced retinopathy model, an effect that is most likely due to the longer half-life of mvsFlt in the vitreous. Taken together, our results indicate that conjugation of sFlt to HyA does not affect its affinity for VEGF and this conjugation significantly improves drug half-life. These in vivo results suggest that our strategy of multivalent conjugation could substantially improve upon drug half-life, and thus the efficacy of currently available drugs that are used in diseases such as diabetic retinopathy, thereby improving patient quality of life.
Investigative Ophthalmology & Visual Science | 2015
Eda Isil Altiok; Tatiana Ecoiffier; Roberto Sessa; Don Yuen; Sammy Grimaldo; Colin Tran; David Li; Michael Rosner; Narae Lee; Toshimitsu Uede; Lu Chen
PURPOSE We recently reported that corneal lymphatic vessels develop integrin alpha-9 (Itga-9)-positive valves during inflammatory lymphangiogenesis. The purpose of this study was to further investigate the role of Itga-9 in corneal lymphatic valve formation in vivo and lymphatic endothelial cell (LEC) functions in vitro. METHODS Standard murine suture placement model was used to study the effect of Itga-9 blockade on lymphatic valve formation in vivo using Itga-9 neutralizing antibody. Whole-mount corneas were harvested for immunofluorescent microscopic analysis. Additionally, human LEC culture system was used to examine the effect of Itga-9 gene knockdown on cell functions using small interfering RNAs (siRNAs). RESULTS Itga-9 blockade in vivo significantly reduced the number of lymphatic valves formed in the inflamed cornea. Moreover, Itga-9 gene knockdown in human LECs suppresses cell functions of proliferation, adhesion, migration, and tube formation. CONCLUSIONS Itga-9 is critically involved in corneal lymphatic valve formation. Further investigation of the Itga-9 pathway may provide novel strategies to treat lymphatic-related diseases occurring both inside and outside the eye.
Biomaterials | 2016
Eda Isil Altiok; Jorge L. Santiago-Ortiz; Felicia L. Svedlund; Aline Zbinden; Amit K. Jha; Deepika Bhatnagar; Peter Loskill; Wesley M. Jackson; David V. Schaffer; Kevin E. Healy
Biomacromolecules | 2016
Felicia L. Svedlund; Eda Isil Altiok; Kevin E. Healy
Archive | 2014
Amit K. Jha; Eda Isil Altiok; Wesley M. Jackson; Kevin E. Healy
Archive | 2016
Kevin E. Healy; Eda Isil Altiok; David V. Schaffer; Wesley M. Jackson
Archive | 2014
Amit K. Jha; Eda Isil Altiok; Wesley M. Jackson; Kevin E. Healy
Archive | 2014
Amit K. Jha; Eda Isil Altiok; Wesley M. Jackson; Kevin E. Healy
Investigative Ophthalmology & Visual Science | 2013
Tan Truong; Eda Isil Altiok; Eric J. Huang; Tatiana Ecoiffier; Don Yuen; Toshimitsu Uede; Lu Chen